Skip to main content

Table 1 Baseline characteristics

From: Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease

  QD → BID (N = 29) BID → QD (N = 32) P Value Overall (N = 61)
Age (years) 60.9 ± 9.8 61.1 ± 8.4 0.925 61.0 ± 9.0
Onset age 51.7 ± 10.8 51.8 ± 7.0 0.857 51.7 ± 8.9
Sex (M:F) 11:18 13:19 1.000 24:37
mUPDRS 20.0 ± 9.5 22.5 ± 8.6 0.170 21.3 ± 9.0
Hoehn and Yahr stage 2.1 ± 0.5 2.4 ± 0.7 0.063 2.2 ± 0.6
Ropinirole PR dose after titration 8.9 ± 5.6 11.0 ± 5.7 0.128 10.0 ± 5.7
LEDD 894.0 ± 392.8 865.9 ± 361.7 0.879 879.2 ± 373.9
Epworth Sleep Scale 6.1 ± 5.5 6.2 ± 5.9 0.353 6.1 ± 5.6
Sleep questionnaire     
  Overall sleep quality 3.8 ± 2.6 2.9 ± 2.7 0.232 3.4 ± 2.7
  Nocturnal off-symptoms 2.5 ± 2.8 3.4 ± 3.7 0.659 3.0 ± 3.3
  Early morning off symptoms 2.9 ± 2.7 3.0 ± 3.9 0.721 3.0 ± 3.8
  1. QD, Once-daily; BID, Twice-daily; mUPDRS, Unified Parkinson’s Disease Rating Scale part 3; PR, prolonged-release; LEDD, levodopa equivalent dose.